Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 303

1.

Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer.

Chen J, Gomes AR, Monteiro LJ, Wong SY, Wu LH, Ng TT, Karadedou CT, Millour J, Ip YC, Cheung YN, Sunters A, Chan KY, Lam EW, Khoo US.

PLoS One. 2010 Aug 20;5(8):e12293. doi: 10.1371/journal.pone.0012293.

PMID:
20808831
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression.

Hui RC, Gomes AR, Constantinidou D, Costa JR, Karadedou CT, Fernandez de Mattos S, Wymann MP, Brosens JJ, Schulze A, Lam EW.

Mol Cell Biol. 2008 Oct;28(19):5886-98. doi: 10.1128/MCB.01265-07. Epub 2008 Jul 21.

PMID:
18644865
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt.

Sunters A, Madureira PA, Pomeranz KM, Aubert M, Brosens JJ, Cook SJ, Burgering BM, Coombes RC, Lam EW.

Cancer Res. 2006 Jan 1;66(1):212-20.

PMID:
16397234
[PubMed - indexed for MEDLINE]
Free Article
4.

Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.

Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Steelman LS, McCubrey JA.

Oncotarget. 2011 Aug;2(8):610-26.

PMID:
21881167
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates.

Li S, Zhou Y, Wang R, Zhang H, Dong Y, Ip C.

Mol Cancer Ther. 2007 Mar;6(3):1031-8. Epub 2007 Mar 5.

PMID:
17339365
[PubMed - indexed for MEDLINE]
Free Article
6.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.

PMID:
16854453
[PubMed - indexed for MEDLINE]
7.

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.

Clin Cancer Res. 2004 Dec 1;10(23):8059-67.

PMID:
15585641
[PubMed - indexed for MEDLINE]
Free Article
8.

Akt-FOXO3a signaling axis dysregulation in human oral squamous cell carcinoma and potent efficacy of FOXO3a-targeted gene therapy.

Fang L, Wang H, Zhou L, Yu D.

Oral Oncol. 2011 Jan;47(1):16-21. doi: 10.1016/j.oraloncology.2010.10.010. Epub 2010 Nov 24.

PMID:
21109483
[PubMed - indexed for MEDLINE]
9.

Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer.

McGovern UB, Francis RE, Peck B, Guest SK, Wang J, Myatt SS, Krol J, Kwok JM, Polychronis A, Coombes RC, Lam EW.

Mol Cancer Ther. 2009 Mar;8(3):582-91. doi: 10.1158/1535-7163.MCT-08-0805. Epub 2009 Mar 10.

PMID:
19276163
[PubMed - indexed for MEDLINE]
Free Article
10.

Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.

Clark AS, West K, Streicher S, Dennis PA.

Mol Cancer Ther. 2002 Jul;1(9):707-17.

PMID:
12479367
[PubMed - indexed for MEDLINE]
Free Article
11.

β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer.

Tenbaum SP, Ordóñez-Morán P, Puig I, Chicote I, Arqués O, Landolfi S, Fernández Y, Herance JR, Gispert JD, Mendizabal L, Aguilar S, Ramón y Cajal S, Schwartz S Jr, Vivancos A, Espín E, Rojas S, Baselga J, Tabernero J, Muñoz A, Palmer HG.

Nat Med. 2012 Jun;18(6):892-901. doi: 10.1038/nm.2772.

PMID:
22610277
[PubMed - indexed for MEDLINE]
12.

Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin.

Ho KK, McGuire VA, Koo CY, Muir KW, de Olano N, Maifoshie E, Kelly DJ, McGovern UB, Monteiro LJ, Gomes AR, Nebreda AR, Campbell DG, Arthur JS, Lam EW.

J Biol Chem. 2012 Jan 6;287(2):1545-55. doi: 10.1074/jbc.M111.284224. Epub 2011 Nov 29.

PMID:
22128155
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a.

Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, Kobayashi R, Hung MC.

Cell. 2004 Apr 16;117(2):225-37. Erratum in: Cell. 2007 Jun 29;129(7):1427-8.

PMID:
15084260
[PubMed - indexed for MEDLINE]
Free Article
14.

Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells.

Hui RC, Francis RE, Guest SK, Costa JR, Gomes AR, Myatt SS, Brosens JJ, Lam EW.

Mol Cancer Ther. 2008 Mar;7(3):670-8. doi: 10.1158/1535-7163.MCT-07-0397.

PMID:
18347152
[PubMed - indexed for MEDLINE]
Free Article
15.

Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.

Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, Cocco L, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, McCubrey JA.

Cell Cycle. 2011 Sep 1;10(17):3003-15. Epub 2011 Sep 1.

PMID:
21869603
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.

Park SS, Kim SW.

Oncol Rep. 2007 Jul;18(1):139-43.

PMID:
17549359
[PubMed - indexed for MEDLINE]
17.

Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications.

Badve S, Collins NR, Bhat-Nakshatri P, Turbin D, Leung S, Thorat M, Dunn SE, Geistlinger TR, Carroll JS, Brown M, Bose S, Teitell MA, Nakshatri H.

Am J Pathol. 2010 May;176(5):2139-49. doi: 10.2353/ajpath.2010.090477. Epub 2010 Mar 12.

PMID:
20228224
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells.

Li Y, Wang Z, Kong D, Li R, Sarkar SH, Sarkar FH.

J Biol Chem. 2008 Oct 10;283(41):27707-16. doi: 10.1074/jbc.M802759200. Epub 2008 Aug 7.

PMID:
18687691
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer.

Habashy HO, Rakha EA, Aleskandarany M, Ahmed MA, Green AR, Ellis IO, Powe DG.

Breast Cancer Res Treat. 2011 Aug;129(1):11-21. doi: 10.1007/s10549-010-1161-z. Epub 2011 Feb 19.

PMID:
21336599
[PubMed - indexed for MEDLINE]
20.

Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.

Weng SC, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, Shapiro CL, Chen CS.

Mol Cancer Ther. 2008 Apr;7(4):800-8. doi: 10.1158/1535-7163.MCT-07-0434.

PMID:
18413793
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk